Toru Hyodo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Toru Hyodo has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
Nobuhito Hirawa
The Committee of International Communication for Academic Research of the Japanese Society for Dialysis Therapy, Bunkyo-Ku, Japan
6 shared publicationsChuluuntsetseg Dorj
Ministry of Health, Sukhbaatar District, Mongolia
3 shared publicationsI. Gde Raka Widiana
Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Udayana University, Denpasar, Indonesia
3 shared publications- Kenichi Kokubo
Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan
3 shared publications - Miho Hida
Kurata Hospital, 4-5-26, Higashishindo, Hiratsuka, Kanagawa, Japan
3 shared publications - Shunichiro Urabe
Department of Clinical Engineering, Eijin Clinic, Hiratsuka, Japan
3 shared publications
Latest Publications
- Open Access
- 6 January 2025
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 11 (1) , 1-11
The present status of dialysis patients in Asian countries as of 2022 from a medical economic point of view
In Japan, Mongolia, and Indonesia, dialysis care has been covered by national health insurance and social welfare programs as of 2022, which covers much of the cost burden. However, the proportion of this burden varies by country and Japan is the only one of these countries in which medical fees are fully covered for all dialysis patients. As systems for dialysis medical care coverage have been established, the number of dialysis patients has increased dramatically in each country. However, the cost of dialysis treatment itself is very high relative to personal income in all countries. This puts pressure on national healthcare budgets and gives rise to concerns about the sustainability of dialysis care in the future. Peritoneal dialysis (PD) is less expensive than hemodialysis (HD) in Mongolia and Indonesia, and a PD-first policy is considered effective in reducing costs. Nevertheless, an overwhelming number of patients still undergo HD. Despite the difficulties faced by these three countries in obtaining funds for dialysis treatment, among Asian countries, Mongolia and Indonesia are considered to have relatively advanced healthcare systems. It is considered that there has been progress in the provision of dialysis treatment subsidies to the citizens of these countries.
- 6 January 2025
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 11 (1) , 1-11
Open AccessThe present status of dialysis patients in Asian countries as of 2022 from a medical economic point of view
In Japan, Mongolia, and Indonesia, dialysis care has been covered by national health insurance and social welfare programs as of 2022, which covers much of the cost burden. However, the proportion of this burden varies by country and Japan is the only one of these countries in which medical fees are fully covered for all dialysis patients. As systems for dialysis medical care coverage have been established, the number of dialysis patients has increased dramatically in each country. However, the cost of dialysis treatment itself is very high relative to personal income in all countries. This puts pressure on national healthcare budgets and gives rise to concerns about the sustainability of dialysis care in the future. Peritoneal dialysis (PD) is less expensive than hemodialysis (HD) in Mongolia and Indonesia, and a PD-first policy is considered effective in reducing costs. Nevertheless, an overwhelming number of patients still undergo HD. Despite the difficulties faced by these three countries in obtaining funds for dialysis treatment, among Asian countries, Mongolia and Indonesia are considered to have relatively advanced healthcare systems. It is considered that there has been progress in the provision of dialysis treatment subsidies to the citizens of these countries.
- Open Access
- 8 November 2024
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 10 (1) , 1-8
The status of dialysis patients in Asian countries under the coronavirus disease 2019 (COVID-19) disaster as of December 2019–June 2023: India
The coronavirus disease 2019 (COVID-19) pandemic affected the entire world with unprecedented impact on the health care and economy of countries. India, the most populous country, faced enormous challenges across its diverse population groups. The end-stage renal disease (ESRD) patients on dialysis, especially hemodialysis, were a high-risk group with inevitable regular hospital visits in contrast to the home peritoneal dialysis group. The unplanned lockdown and home confinement posed many risks to dialysis patients due to dialysis unit closures, logistical issues, and severe COVID-19-related morbidities. We have paucity of data on mortality of dialysis patients in India. We describe the reported and available data on COVID-19 in India from across different centers. The vaccination provided by two different pharmaceuticals such as Covaxin and Covishield in a small cohort of dialysis patients reduced infection and severity.
- 8 November 2024
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 10 (1) , 1-8
Open AccessThe status of dialysis patients in Asian countries under the coronavirus disease 2019 (COVID-19) disaster as of December 2019–June 2023: India
The coronavirus disease 2019 (COVID-19) pandemic affected the entire world with unprecedented impact on the health care and economy of countries. India, the most populous country, faced enormous challenges across its diverse population groups. The end-stage renal disease (ESRD) patients on dialysis, especially hemodialysis, were a high-risk group with inevitable regular hospital visits in contrast to the home peritoneal dialysis group. The unplanned lockdown and home confinement posed many risks to dialysis patients due to dialysis unit closures, logistical issues, and severe COVID-19-related morbidities. We have paucity of data on mortality of dialysis patients in India. We describe the reported and available data on COVID-19 in India from across different centers. The vaccination provided by two different pharmaceuticals such as Covaxin and Covishield in a small cohort of dialysis patients reduced infection and severity.
- Open Access
- 4 October 2024
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 10 (1) , 1-12
The status of dialysis patients in Asian countries under COVID-19 disaster as of December 2019–June 2022: Vietnam, Indonesia, and Mongolia
On 1 December 2019, an outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China, and quickly spread around the world. In an effort to prevent transmission, global traffic flows were affected and lectures by international speakers at the 2022 Annual Meeting of the Japanese Society for Dialysis Therapy were streamed over the internet. Speakers from Vietnam, Indonesia, and Mongolia reported on the status of COVID-19 infection in dialysis patients from December 2019 to June 2022. In addition, the situation in Japan is discussed in the introduction. In Japan, the mortality rate due to COVID-19 infection in dialysis patients was approximately 20% in a national statistical survey before the introduction of the vaccine, and decreased to 3.1% with the introduction of the vaccine. In Vietnam, the mortality rate was 42% in non-vaccinated recipients and 21% in two-dose recipients, but this was reported by a single center. Mortality among dialysis patients with COVID-19 infection in Indonesia was 57%, although reported by a single center. In Indonesia, 6 million people were infected with COVID-19, and the number of COVID-19 cases among dialysis patients was estimated to be around 52,200. Mongolia was considered to be the country that was able to move to vaccination while most effectively controlling the domestic spread of severe acute respiratory syndrome coronavirus 2 compared with many other countries.
- 4 October 2024
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 10 (1) , 1-12
Open AccessThe status of dialysis patients in Asian countries under COVID-19 disaster as of December 2019–June 2022: Vietnam, Indonesia, and Mongolia
On 1 December 2019, an outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China, and quickly spread around the world. In an effort to prevent transmission, global traffic flows were affected and lectures by international speakers at the 2022 Annual Meeting of the Japanese Society for Dialysis Therapy were streamed over the internet. Speakers from Vietnam, Indonesia, and Mongolia reported on the status of COVID-19 infection in dialysis patients from December 2019 to June 2022. In addition, the situation in Japan is discussed in the introduction. In Japan, the mortality rate due to COVID-19 infection in dialysis patients was approximately 20% in a national statistical survey before the introduction of the vaccine, and decreased to 3.1% with the introduction of the vaccine. In Vietnam, the mortality rate was 42% in non-vaccinated recipients and 21% in two-dose recipients, but this was reported by a single center. Mortality among dialysis patients with COVID-19 infection in Indonesia was 57%, although reported by a single center. In Indonesia, 6 million people were infected with COVID-19, and the number of COVID-19 cases among dialysis patients was estimated to be around 52,200. Mongolia was considered to be the country that was able to move to vaccination while most effectively controlling the domestic spread of severe acute respiratory syndrome coronavirus 2 compared with many other countries.
- Open Access
- 18 October 2022
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 8 (1) , 1-15
Present status of renal replacement therapy in lower-middle-income Asian countries: Cambodia, Myanmar, Laos, Vietnam, Mongolia, and Bhutan as of June 2019 (before COVID-19), from the interviews of leading doctors in every country: (duplicated English publication from “the special Japanese edition of educational lectures in the 64th annual meeting of the Japanese Society for Dialysis Therapy”)
The present status of Cambodia, Myanmar, Laos, Vietnam, Mongolia, and Bhutan as of June 2019 was reviewed from the interviews of leading doctors in every country. The timing was until just 6 months before the COVID-19 pandemic broke out. The cost per hemodialysis session was 25–70 US dollar and expensive if it is compared with average monthly income of every country. In Cambodia and Laos, patients must cover 100% of expenses for maintenance hemodialysis, in Myanmar, the government covers the cost of once-weekly dialysis sessions, in Vietnam, the government covers 80% of the cost, and in Mongolia and Bhutan, the cost is fully covered by the government. Continuous ambulatory peritoneal dialysis was widely available in Vietnam and Mongolia, which have achieved a relative standard of social infrastructure, but is far from common in any of the other countries. The number of patients on dialysis is increasing with economic development in all countries. Diabetic nephropathy is a common primary reason for dialysis. None of the countries discussed in this article had clinical engineers who could maintain hemodialysis equipment and carry out clinical tasks in dialysis centers. Hospitals were not maintaining their equipment, and damaged units were kept in storage to be used for spare parts. None of the countries had dieticians to provide patients with dietary guidance. Establishment and training of both clinical engineers and registered dietitians are major projects that must be undertaken.
- 18 October 2022
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 8 (1) , 1-15
Open AccessPresent status of renal replacement therapy in lower-middle-income Asian countries: Cambodia, Myanmar, Laos, Vietnam, Mongolia, and Bhutan as of June 2019 (before COVID-19), from the interviews of leading doctors in every country: (duplicated English publication from “the special Japanese edition of educational lectures in the 64th annual meeting of the Japanese Society for Dialysis Therapy”)
The present status of Cambodia, Myanmar, Laos, Vietnam, Mongolia, and Bhutan as of June 2019 was reviewed from the interviews of leading doctors in every country. The timing was until just 6 months before the COVID-19 pandemic broke out. The cost per hemodialysis session was 25–70 US dollar and expensive if it is compared with average monthly income of every country. In Cambodia and Laos, patients must cover 100% of expenses for maintenance hemodialysis, in Myanmar, the government covers the cost of once-weekly dialysis sessions, in Vietnam, the government covers 80% of the cost, and in Mongolia and Bhutan, the cost is fully covered by the government. Continuous ambulatory peritoneal dialysis was widely available in Vietnam and Mongolia, which have achieved a relative standard of social infrastructure, but is far from common in any of the other countries. The number of patients on dialysis is increasing with economic development in all countries. Diabetic nephropathy is a common primary reason for dialysis. None of the countries discussed in this article had clinical engineers who could maintain hemodialysis equipment and carry out clinical tasks in dialysis centers. Hospitals were not maintaining their equipment, and damaged units were kept in storage to be used for spare parts. None of the countries had dieticians to provide patients with dietary guidance. Establishment and training of both clinical engineers and registered dietitians are major projects that must be undertaken.
- Open Access
- 28 March 2022
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 8 (1) , 1-11
Current status of renal replacement therapy in Cambodia and Japanese support activities in developing countries in East and Southeast Asia: a report as of June 2018 from the Non-Western World Countries Symposium at the 63rd Annual Meeting of the Japanese Society for Dialysis Therapy
- 28 March 2022
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 8 (1) , 1-11
Open AccessCurrent status of renal replacement therapy in Cambodia and Japanese support activities in developing countries in East and Southeast Asia: a report as of June 2018 from the Non-Western World Countries Symposium at the 63rd Annual Meeting of the Japanese Society for Dialysis Therapy
- 28 February 2022
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 25 (4) , 377-381
Continuous intradialytic amino acid infusion from the start of dialysis is better to avoid catabolism under the high-volume pre-dilution on-line HDF
It was reported that amino acid infusion during hemodialysis is useful for improving nutritional status. The optimal administration method of amino acid infusion under the high-volume pre-dilution on-line HDF (HVPO-HDF) was analyzed in this study. Subjects were 10 patients on maintenance dialysis at our clinic. We performed high-volume pre-dilution on-line HDF. We investigated two methods for administration of Neoamiyu® 200-ml total amino acid (TAA) infusion for patients with renal failure: (1) continuous infusion into the dialysis circuit for 4 h from the start of dialysis to its completion (infusion rate 50 ml/h) and (2) continuous infusion started 1 h before completion of dialysis (infusion rate 200 ml/h), and compared pre- and post-dialysis blood concentrations and leakage of TAA, essential amino acids (EAA), and nonessential amino acids (NEAA) between these methods. Pre-dialysis blood concentrations of amino acids showed no difference between both the groups. Post-dialysis blood concentrations of amino acids were higher in all concentrations were significantly higher with continuous infusion starting 1 h before completion of dialysis. Leakage of amino acids showed no difference between both the groups. The continuous intradialytic amino acid infusion from the start of dialysis is better to avoid catabolism under high-volume pre-dilution on-line HDF.
- 28 February 2022
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 25 (4) , 377-381
Continuous intradialytic amino acid infusion from the start of dialysis is better to avoid catabolism under the high-volume pre-dilution on-line HDF
It was reported that amino acid infusion during hemodialysis is useful for improving nutritional status. The optimal administration method of amino acid infusion under the high-volume pre-dilution on-line HDF (HVPO-HDF) was analyzed in this study. Subjects were 10 patients on maintenance dialysis at our clinic. We performed high-volume pre-dilution on-line HDF. We investigated two methods for administration of Neoamiyu® 200-ml total amino acid (TAA) infusion for patients with renal failure: (1) continuous infusion into the dialysis circuit for 4 h from the start of dialysis to its completion (infusion rate 50 ml/h) and (2) continuous infusion started 1 h before completion of dialysis (infusion rate 200 ml/h), and compared pre- and post-dialysis blood concentrations and leakage of TAA, essential amino acids (EAA), and nonessential amino acids (NEAA) between these methods. Pre-dialysis blood concentrations of amino acids showed no difference between both the groups. Post-dialysis blood concentrations of amino acids were higher in all concentrations were significantly higher with continuous infusion starting 1 h before completion of dialysis. Leakage of amino acids showed no difference between both the groups. The continuous intradialytic amino acid infusion from the start of dialysis is better to avoid catabolism under high-volume pre-dilution on-line HDF.
- Open Access
- 10 August 2021
- Published by MDPI AG in Kidney and Dialysis
- Vol. 1 (1) , 53-60
Overseas Support in the Field of Vascular Access
Since joining the Non-Governmental Organization Ubiquitous Blood Purification International in 2014, professionals who are mainly members of the Japanese Society for Dialysis Therapy (JSDT) have worked toward promoting dialysis therapy in several countries through help with organization of local nephrology societies and conducting educational activities. Since 2016, training at our hospital has been provided for doctors and dialysis staff from these countries as part of the activities of the JSDT. These activities also involve technical training for vascular access (VA) surgery and management. To date, lectures and practical teaching on VA procedures have been given in Cambodia and Vietnam, and a hands-on seminar on echo-guided puncture and VA management was held in Mongolia. In Mongolia and Myanmar, a plan to provide systemic VA surgery education has been developed, at the request of local nephrology societies. Doctors and medical staff from Vietnam, Laos, Cambodia, Nepal and Indonesia have visited our hospital and have observed operations as part of their training. To achieve sustainable medical support and academic activities, we have found it to be important to have a counterpart society in each country, and guidance has been provided when required on organization of a national nephrology society.
- 10 August 2021
- Published by MDPI AG in Kidney and Dialysis
- Vol. 1 (1) , 53-60
Open AccessOverseas Support in the Field of Vascular Access
Since joining the Non-Governmental Organization Ubiquitous Blood Purification International in 2014, professionals who are mainly members of the Japanese Society for Dialysis Therapy (JSDT) have worked toward promoting dialysis therapy in several countries through help with organization of local nephrology societies and conducting educational activities. Since 2016, training at our hospital has been provided for doctors and dialysis staff from these countries as part of the activities of the JSDT. These activities also involve technical training for vascular access (VA) surgery and management. To date, lectures and practical teaching on VA procedures have been given in Cambodia and Vietnam, and a hands-on seminar on echo-guided puncture and VA management was held in Mongolia. In Mongolia and Myanmar, a plan to provide systemic VA surgery education has been developed, at the request of local nephrology societies. Doctors and medical staff from Vietnam, Laos, Cambodia, Nepal and Indonesia have visited our hospital and have observed operations as part of their training. To achieve sustainable medical support and academic activities, we have found it to be important to have a counterpart society in each country, and guidance has been provided when required on organization of a national nephrology society.
- Open Access
- 14 December 2020
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 6 (1) , 1-14
Present status of renal replacement therapy in Asian countries as of 2017: Vietnam, Myanmar, and Cambodia
- 14 December 2020
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 6 (1) , 1-14
Open AccessPresent status of renal replacement therapy in Asian countries as of 2017: Vietnam, Myanmar, and Cambodia
- 16 May 2020
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 23 (4) , 342-347
Amino acid losses are lower during pre-dilution on-line HDF than HD of the same Kt/V for urea
In this study, we investigated differences in amino acid losses between HD and pre-dilution on-line HDF with equal Kt/V for urea to determine which modality removes less amino acids from extravascular pools and ensures better nutrition. The subjects were patients receiving pre-dilution on-line HDF (n = 10) or HD (n = 10) at this hospital. Dialysis time was 4 h for all patients. In patients on HD, the blood flow rate was 200 mL/min and the dialysate flow rate was 463 ± 29.3 mL/min. In patients on pre-dilution on-line HDF, the blood flow rate was 240 ± 20 mL/min, the dialysate flow rate was 565.0 ± 42.5 mL/min, and the substitution flow rate (substitution volume) was 252.8 ± 26.4 mL/min (57.0 ± 6.0 L). Kt/V for urea was comparable between patients on HD and patients on pre-dilution on-line HDF (1.46 ± 0.25 vs. 1.46 ± 0.31). Amino acid loss and clear space were evaluated. Patients on pre-dilution on-line HDF lost significantly less glutamine and arginine (p < 0.01 and p = 0.032) and significantly less nonessential amino acids (NEAAs) than patients on HD (p = 0.013). They also had significantly lower clear space of total amino acids (TAAs), NEAAs, essential amino acids (EAAs), and branched-chain amino acids (BCAAs) than patients on HD (Total AA p = 0.019, NEAA p = 0.018, EAA p = 0.024, BCAA p = 0.042). When Kt/V for urea is equal, pre-dilution on-line HDF ensures better nutrition than does HD.
- 16 May 2020
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 23 (4) , 342-347
Amino acid losses are lower during pre-dilution on-line HDF than HD of the same Kt/V for urea
In this study, we investigated differences in amino acid losses between HD and pre-dilution on-line HDF with equal Kt/V for urea to determine which modality removes less amino acids from extravascular pools and ensures better nutrition. The subjects were patients receiving pre-dilution on-line HDF (n = 10) or HD (n = 10) at this hospital. Dialysis time was 4 h for all patients. In patients on HD, the blood flow rate was 200 mL/min and the dialysate flow rate was 463 ± 29.3 mL/min. In patients on pre-dilution on-line HDF, the blood flow rate was 240 ± 20 mL/min, the dialysate flow rate was 565.0 ± 42.5 mL/min, and the substitution flow rate (substitution volume) was 252.8 ± 26.4 mL/min (57.0 ± 6.0 L). Kt/V for urea was comparable between patients on HD and patients on pre-dilution on-line HDF (1.46 ± 0.25 vs. 1.46 ± 0.31). Amino acid loss and clear space were evaluated. Patients on pre-dilution on-line HDF lost significantly less glutamine and arginine (p < 0.01 and p = 0.032) and significantly less nonessential amino acids (NEAAs) than patients on HD (p = 0.013). They also had significantly lower clear space of total amino acids (TAAs), NEAAs, essential amino acids (EAAs), and branched-chain amino acids (BCAAs) than patients on HD (Total AA p = 0.019, NEAA p = 0.018, EAA p = 0.024, BCAA p = 0.042). When Kt/V for urea is equal, pre-dilution on-line HDF ensures better nutrition than does HD.
- 27 March 2019
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 22 (3) , 253-255
Restless legs syndrome effectively treated with constant-pressure predilution online hemodiafiltration
We encountered a case of unstable predilution online HDF due to elevated transmembrane pressure (TMP) when performing constant-speed predilution online hemodiafiltration (HDF) as treatment for restless legs syndrome (RLS) in a dialysis patient. We report the effectiveness of incorporating a newly developed constant-pressure predilution online HDF system as a preventive measure against unstable online HDF and frequent adjustment of settings when treating dialysis patients with RLS.
- 27 March 2019
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 22 (3) , 253-255
Restless legs syndrome effectively treated with constant-pressure predilution online hemodiafiltration
We encountered a case of unstable predilution online HDF due to elevated transmembrane pressure (TMP) when performing constant-speed predilution online hemodiafiltration (HDF) as treatment for restless legs syndrome (RLS) in a dialysis patient. We report the effectiveness of incorporating a newly developed constant-pressure predilution online HDF system as a preventive measure against unstable online HDF and frequent adjustment of settings when treating dialysis patients with RLS.